ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,554Medicare Part D Prescriptions Filled, Including Refills

Rank: 767 out of 3734

$425K Total Retail Price of All Prescriptions

Rank: 971 out of 3734

458 Patients Receiving at Least One Drug in Part D
65%Patients 65 Years and Older
68% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Pennsylvania
Lower avg

Schedule Two
Controlled Substances

10% of this provider’s 458 patients filled at least one prescription for a schedule two drug, compared to an average of 6%.

Schedule Three
Controlled Substances

10% of this provider’s 458 patients filled at least one prescription for a schedule three drug, compared to an average of 8%.

Risky Drugs to Seniors

1% of this provider’s 4,873 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

23% of this provider’s prescriptions were for brand-name drugs, compared to an average of 24%.

Prescription Price

$50 was the average price of a prescription from this provider, compared to $57 among peers.

Prescriptions per Patient

19 is the average number of prescriptions (including refills) per patient, compared to an average of 19.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Pennsylvania
LISINOPRIL 347 181 1 3
AMLODIPINE BESYLATE 336 285 2 5
LEVOTHYROXINE SODIUM 288 143 3 2
OMEPRAZOLE 285 155 4 4
LOVASTATIN 236 170 5 41
METOPROLOL TARTRATE 230 135 6 6
FUROSEMIDE 225 146 7 7
METFORMIN HCL 203 143 8 8
SIMVASTATIN 194 109 9 1
WARFARIN SODIUM 190 145 10 10
ZOLPIDEM TARTRATE 188 92 11 24
HYDROCHLOROTHIAZIDE 152 94 12 9
HYDROCODONE-ACETAMINOPHEN 148 47 S3 13 12
ATENOLOL 129 102 14 13
ATORVASTATIN CALCIUM 97 65 15 11
GABAPENTIN 92 61 16 17
VENTOLIN HFA 85 35 17 70
CLOPIDOGREL 84 58 18 23
IBUPROFEN 82 22 19 75
GLIMEPIRIDE 81 57 20 37
ACETAMINOPHEN-CODEINE 80 30 S3 21 123
ENDOCET 80 0 S2 21 89
SERTRALINE HCL 79 59 23 18
OXYCODONE-ACETAMINOPHEN 76 39 S2 24 51
ENALAPRIL MALEATE 75 39 25 63
ESCITALOPRAM OXALATE 75 24 25 68
LOSARTAN POTASSIUM 69 55 27 21
PRAVASTATIN SODIUM 61 44 28 15
ADVAIR DISKUS 61 20 28 35
AZITHROMYCIN 61 37 28 38
PROAIR HFA 60 30 31 83
CYMBALTA 58 0 32 67
GLIPIZIDE 57 30 33 57
PLAVIX 57 41 33 39
GLIPIZIDE XL 56 43 35 85
ALLOPURINOL 55 32 36 33
CIPROFLOXACIN HCL 54 30 37 77
CRESTOR 52 51 38 28
MUPIROCIN 52 33 38 189
SPIRIVA 51 25 40 40
FLUTICASONE PROPIONATE 51 11 40 46
LISINOPRIL-HYDROCHLOROTHIAZIDE 51 37 40 27
CLONIDINE HCL 51 39 40 79
DIOVAN 51 31 40 31
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Oct. 10, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.